Small Pharma Expands Intellectual Property Portfolio

“Since the previous IP portfolio update on February 1, 2023, the Company has secured five new granted patents, with three more expected to be granted by May 31, 2023. Additionally, it has received five patent Notices of Allowance.”

These are the main highlights found in Small Pharma’s IP update announced yesterday. The DMT-focused drug development firm is building on its successful Phase 2 results by expanding its already solid intellectual property portfolio.

According to Small Pharma’s press release below, the “… additional IP covers the four focused areas of protection and multiple markets, strengthening the Company’s international IP position”.

Analyst Elemer Piros of EF Hutton believes this supports Small Pharma’s chances — and has reiterated his Buy rating and very bullish price prediction. See the note here.

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

May 25, 2023 – London, United Kingdom – Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP“) portfolio, demonstrating significant progress already made by the Company in 2023.

Small Pharma aims to protect its pipeline programs through a multi-layered IP strategy with four core areas of protection. These areas of protection include: Composition of Matter, covering novel drug substances; Medical Use, covering therapeutic compositions and medical uses thereof; Drug Product, covering pharmaceutical formulations; and Synthetic Route, covering the novel and efficient synthesis of high purity drug substance at scale.

Since the previous IP portfolio update on February 1, 2023, the Company has secured five new granted patents, with three more expected to be granted by May 31, 2023. Additionally, it has received five patent Notices of Allowance. The additional IP covers the four focused areas of protection and multiple markets, strengthening the Company’s international IP position.

The new patent grants and Notices of Allowance are summarized below.

As of May 24, 2023, Small Pharma’s IP portfolio consists of 19 granted patents, with 97 allowed or pending. The protection covering each of the Company’s pipeline programs is outlined below.

George Tziras, Chief Executive Officer of Small Pharma said:

Our team has made great progress this year to further strengthen our proprietary IP position in key international markets. We continue to build multi-layered IP protection around each of our pipeline programs, helping to optimize their commercial potential. We are pleased that our efforts to invest in developing novel treatment innovations for patients continues to be recognized in multiple jurisdictions.”

About Small Pharma

Small Pharma is a biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. The Company’s current focus is on exploring new therapeutic approaches for depression. Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of N, N-dimethyltryptamine. The Company is advancing clinical programs of SPL026 and SPL028 with supportive therapy for the treatment of mental health conditions, and was granted an Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”) for IV SPL026 with supportive therapy for Major Depressive Disorder. In addition, Small Pharma has a pipeline of proprietary preclinical assets in development.

The post Small Pharma Expands Intellectual Property Portfolio appeared first on Microdose.

Read More